HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Actinium Pharma (AMEX:ATNM) and maintained a $50 price target, as stated by analyst Joseph Pantginis.
June 17, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Actinium Pharma and maintained a $50 price target, indicating continued confidence in the company's growth potential.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for investors. It suggests confidence in the company's future performance and could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100